A biotech that uses artificial intelligence to assist its drug discovery efforts has relocated its headquarters from New York ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Secondcell Bio, a U.S. BioTech company scaling-up the its platform technology invented at The Rockefeller University in the ...

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results ...

Ins("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule ...

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class ...

A new generation of longevity biotech companies with a more conservative approach than their predecessors has emerged—but ...

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration ...

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with ...

With the help of Insilico Medicine's research and development team in Shanghai, the globally leading AI-driven biotech company has condensed preclinical drug development from multiple years into ...